IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

2024.01.14
The 12th International AIDS Association HIV Science Conference (IAS 2023) was held in Brisbane, Australia from July 23 to 26, 2023. In the oral reports of the conference, experts from the World Health Organization (WHO) reported that global monitoring data for MPOX in 2022 showed that half of the patients with MPOX were HIV carriers. However, HIV is not a risk factor for increased hospitalization due to MPOX. Another study based on interviews with MPOX patients in Australia indicated that most patients had negative experiences with the disease and sequelae related to MPOX.
IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV

IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV

2024.01.14
People Living With HIV (PLWH) are at high risk of active tuberculosis (TB). Guidelines both domestically and internationally suggest that PLWH with positive latent tuberculosis infection (LTBI) screening and those with a history of close contact with active TB should receive TB preventive treatment. However, commonly used preventive treatment regimens such as rifampin and rifapentine have potential drug interactions with HIV antiretroviral therapy (ART). A multi-center retrospective study from Taiwan, China, presented at the 12th International AIDS Society HIV Science Conference (IAS 2023) showed that ART based on integrase inhibitors (INSTIs) combined with rifapentine-based short-course TB preventive treatment does not affect the patient's sustained HIV virologic suppression rate.